[1]杜振华*,魏茜雪.重组人促红素联合蔗糖铁治疗妇科恶性肿瘤相关性贫血的疗效及不良反应观察[J].中国计划生育和妇产科,2016,(12):21- 23,32.
　DU Zhen-hua*,WEI Qian-xue.Observation of curative effect and adverse reaction of recombinant human erythropoietin combined with sucrose iron in the treatment of gynecological malignant tumor related anemia[J].Chinese Journal of Family Planning & Gynecotokology,2016,(12):21- 23,32.
点击复制

重组人促红素联合蔗糖铁治疗妇科恶性肿瘤相关性贫血的疗效及不良反应观察
分享到：

《中国计划生育和妇产科》[ISSN:1674-4020/CN:51-1708/R]

卷:
期数:
2016年12期
页码:
21- 23,32
栏目:
论著与临床
出版日期:
2016-12-30

文章信息/Info

Title:
Observation of curative effect and adverse reaction of recombinant human erythropoietin combined with sucrose iron in the treatment of gynecological malignant tumor related anemia
作者:
杜振华*; 魏茜雪
中国医科大学附属盛京医院妇产科
Author(s):
DU Zhen-hua*; WEI Qian-xue
Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang Liaoning 110004, P.R.China
关键词:
重组人促红素; 肿瘤相关性贫血; 妇科肿瘤
Keywords:
recombinant human erythropoietin; tumor associated anemia;  gynecologic tumor
分类号:
R 473. 71
摘要:
目的观察重组人促红素联合蔗糖铁治疗妇科肿瘤相关性贫血的临床效果及不良反应。方法选取2014年1月至2016年4月在中国医科大学附属盛京医院就诊的妇科肿瘤相关性贫血患者82例，其中观察组42例，对照组40例。观察组给予重组人促红素注射液联合蔗糖铁注射液治疗及预防贫血，重组人促红素注射液150 IU/kg/次皮下注射，每周3次。蔗糖铁注射液200 mg静脉注射，每周3次，连续8周。对照组血红蛋白（hemoglobin, HB)＞80g/L时，未予升血治疗而仅行化疗。观察两组治疗前及治疗后的红细胞（red blood cell，RBC）计数,HB、红细胞比容(hematocrit，HCT)及不良反应。结果观察组治疗后RBC、HB、HCT均高于治疗前，且均高于对照组，差异有统计学意义(P<005)；对照组8周后RBC、HB、HCT均低于化疗前，差异有统计学意义(P<005)。观察组无血栓等不良反应发生。结论化疗可加重妇科肿瘤相关性贫血，而重组人促红素联合蔗糖铁治疗妇科肿瘤相关性贫血，临床效果显著。
Abstract:
ObjectiveTo observe the clinical effect and adverse reaction of recombinant human erythropoietin injection combined with iron sucrose injection in the treatment of patients with gynecological tumor associated anemia. Methods82 cases of gynecological tumor associated anemia patients in Shengjing Hospital of China Medical University from Jannuary 2014 to April 2016 were divided into observation group (42 cases) and control group (40 cases). The observation group received combined treatment of recombinant human erythropoietin injection and iron sucrose injection. Recombinant human erythropoietin injection 150IU/Kg/ hypodermic injection, 3 times a week. Iron sucrose injection 200mg intravenous injection, 3 times a week for 8 weeks.When in the control growp HB＞80g/L,only gave chemotheropy without treatment to rise HB. Before and after treatment, the red blood cell count (RBC), hemoglobin (HB), hematocrit (HCT) and adverse reactions were observed in the two groups. ResultsRBC, HB and HCT of the observation group post treatment were higher than those before treatment, and were higher than the control group. The differences were statistically significant (P<005). RBC, HB and HCT after 8 weeks of the control group were lower than that before chemotherapy, the differences were statistically significant (P<005). No thrombosis and other adverse reactions were observed in the observation group. ConclusionChemotherapy can aggravate gynecological tumor associated anemia. And the clinical effect of recombinant human erythropoietin injection combined with iron sucrose injection as the treatment of gynecological tumor associated anemia is remarkable.

参考文献/References:

［1］董志强，任秀梅，杜更全．促红细胞生成素治疗肿瘤相关性贫血的疗效观察 ［J］．河北医药，2013，35（3）：388-389． ［2］王艾娟，陈丽梅，郭晓静．促红细胞生成素治疗肿瘤相关性贫血临床分析 ［J］．临床和实验医学杂志，2014，13（10）：860-862． ［3］王曙光，王仪胜．促红细胞生成素治疗肿瘤相关性贫血的临床观察 ［J］．蚌埠医学院学报，2013，38（2）：186-188． ［4］杨前生．促红细胞生成素治疗肿瘤相关性贫血临床分析 ［J］．医学信息，2014，27（18）：231． ［5］TANG C M, YU Jun. Hypoxia-inducible factor-1 as a therapeutic target in cancer ［J］. Journal of Gastroenterology and Hepatology, 2013, 28(3): 401-405. ［6］BABA Yoshifumi, NOSHO K, SHIMA Kaori, et al. HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers ［J］. The American Journal of Pathology, 2010, 176(5): 2292-2301. ［7］DANG D T, CHUN Sang-y, BURKITT K, et al. Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition ［J］. Cancer Research, 2008, 68(6): 1872-1880. ［8］李学梅．促红细胞生成素治疗肿瘤相关性贫血的临床分析 ［J］．检验医学与临床，2014，11（16）：2299-2300． ［9］HARADA H, OMURA K. Preoperative concurrent chemotherapy with S-1 and radiotherapy for locally advanced squamous cell carcinoma of the oral cavity: Phase I trial ［J］. Journal of Experimental & Clinical Cancer Research, 2010, 29(1): 33. ［10］王杰军．重组人红细胞生成素治疗肿瘤相关性贫血临床应用分析 ［J］．癌症进展，2012，10 （2）：103-110． ［11］相娜娜．肿瘤相关性贫血的研究进展 ［J］．肿瘤基础与临床，2013，26 （2）：159-162． ［12］吴付兵，王星，王康霞，等．促红细胞生成素对胃癌相关性贫血患者的疗效 ［J］．现代肿瘤医学，2015，23（2）：241-243． ［13］曾红梅．重组人促红细胞生成素联合铁剂治疗肿瘤相关性贫血的疗效分析 ［J］．现代诊断与治疗，2013，24（6）：1373-1374． ［14］孙莹．重组人促红细胞生成素联合蔗糖铁治疗肿瘤相关性贫血29例临床疗效观察 ［J］．中国医药指南，2013，11（22）：571-573． ［15］乔姝，杨丽，白强．促红细胞生成素对肿瘤性贫血的临床应用研究 ［J］．中国医学创新，2013，10 （30）：3-4． ［16］KOUROUNIS G, IATRAKIS G, CHRONOPOULOS K, et al. The use of erythropoietin in gynecologic cancer patients ［J］. European Journal of Gynaecological Oncology, 2004, 25(6): 735-736. ［17］Raritan, NJ. Data from the EPO-ANE-3010 study evaluating epoetinalfa presented at San Antonio Breast Cancer Symposium［EB/OL］. (2014-12-12).

更新日期/Last Update: 2016-12-25